AACR IO 2027: What to Expect From the Immuno-Oncology Conference Coming to Los Angeles

What this article covers
- What This Article Covers
- A. Live in Los Angeles, California.
- What the Conference Covers
- AACR IO is built around the mechanisms and clinical translation of anti-cancer immune responses rather than oncology writ large. Past programming (the February 2026 edition, held in advance of this one) centered on cancer vaccine development, engineering T cells to withstand and function within the hostile tumor microenvironment, next-generation CAR T-cell constructs, and "chimeric" immune-cell approaches designed to breach solid-tumor defenses that have historically blunted cellular therapies.
- Who Attends, and Why It Matters
- The conference draws a mix of academic immunologists, oncologists, drug developers, and biotech and pharma scientists — a smaller, more specialized crowd than AACR's flagship Annual Meeting or ASCO. For researchers and clinicians, that specificity is the draw: sessions go deeper into mechanism (how a given engineered T cell actually overcomes tumor immunosuppression, for instance) than a general oncology congress typically allows.
- Key Themes to Watch
- Based on the AACR IO 2026 program and the stated 2027 theme, attendees should watch for sessions on: next-generation cancer vaccines (a resurgent area following renewed interest in neoantigen- and mRNA-based platforms); strategies to make CAR T-cell and other engineered cell therapies effective against solid tumors, where response rates have lagged far behind blood cancers; and combination approaches pairing cellular or vaccine therapies with checkpoint inhibitors or other immune modulators. Clinical trial and late-breaking abstracts — submitted closer to the meeting date, with a January 27, 2027 deadline — will carry the most clinically relevant updates, including safety and adverse-event data that matter as much to the field's direction as efficacy headlines do.
- Bottom Line
- AACR IO 2027 is a real, confirmed meeting — not yet widely covered as "the next big thing" the way larger congresses are, but a genuinely useful one for anyone tracking where cancer immunotherapy research is actually heading, from engineered cell therapies to cancer vaccines. As with any early-stage science presented at a research conference, readers should treat session highlights as hypothesis-generating signals rather than confirmed treatment advances: most of what's discussed will still be years from regulatory approval, if it gets there at all, and this site does not endorse or recommend any specific therapy, product, or provider connected to the meeting.
What This Article Covers
The American Association for Cancer Research's Immuno-Oncology Conference (AACR IO 2027) will convene February 28 through March 3, 2027, at the JW Marriott Los Angeles L.A. Live in Los Angeles, California. Titled "Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy," the meeting is one of the field's most tightly focused scientific gatherings, drawing basic researchers, clinicians, and industry scientists working specifically on cancer immunology and immunotherapy — a complement to AACR's much larger Annual Meeting, which covers oncology broadly rather than immunotherapy alone.
What the Conference Covers
AACR IO is built around the mechanisms and clinical translation of anti-cancer immune responses rather than oncology writ large. Past programming (the February 2026 edition, held in advance of this one) centered on cancer vaccine development, engineering T cells to withstand and function within the hostile tumor microenvironment, next-generation CAR T-cell constructs, and "chimeric" immune-cell approaches designed to breach solid-tumor defenses that have historically blunted cellular therapies. The 2027 program is expected to build on these threads, with sessions spanning basic immunology, translational research, and late-breaking clinical trial data — the kind of early-stage results that often shape how CAR T, cancer vaccines, and T-cell engineering are discussed in the following year's larger meetings. Importantly, many of these therapies remain investigational: most cancer vaccine platforms and several engineered T-cell approaches discussed at AACR IO have not completed the rigorous, placebo- or standard-of-care-controlled trials required for FDA approval, and attendees should expect to hear hedged, early-phase data rather than confirmed clinical benefit for every approach presented.
Who Attends, and Why It Matters
The conference draws a mix of academic immunologists, oncologists, drug developers, and biotech and pharma scientists — a smaller, more specialized crowd than AACR's flagship Annual Meeting or ASCO. For researchers and clinicians, that specificity is the draw: sessions go deeper into mechanism (how a given engineered T cell actually overcomes tumor immunosuppression, for instance) than a general oncology congress typically allows. For industry and investors, AACR IO has become a venue where companies share updated data on cell therapies, bispecific antibodies, and immune-modulating agents still in clinical development — making it a useful early signal of which approaches are advancing and which are stalling, well before pivotal trial readouts reach a journal or an FDA panel.
Key Themes to Watch
Based on the AACR IO 2026 program and the stated 2027 theme, attendees should watch for sessions on: next-generation cancer vaccines (a resurgent area following renewed interest in neoantigen- and mRNA-based platforms); strategies to make CAR T-cell and other engineered cell therapies effective against solid tumors, where response rates have lagged far behind blood cancers; and combination approaches pairing cellular or vaccine therapies with checkpoint inhibitors or other immune modulators. Clinical trial and late-breaking abstracts — submitted closer to the meeting date, with a January 27, 2027 deadline — will carry the most clinically relevant updates, including safety and adverse-event data that matter as much to the field's direction as efficacy headlines do.
Bottom Line
AACR IO 2027 is a real, confirmed meeting — not yet widely covered as "the next big thing" the way larger congresses are, but a genuinely useful one for anyone tracking where cancer immunotherapy research is actually heading, from engineered cell therapies to cancer vaccines. As with any early-stage science presented at a research conference, readers should treat session highlights as hypothesis-generating signals rather than confirmed treatment advances: most of what's discussed will still be years from regulatory approval, if it gets there at all, and this site does not endorse or recommend any specific therapy, product, or provider connected to the meeting.
Key Questions Answered
- When and where is AACR IO 2027?
- The meeting is scheduled for February 28 through March 3, 2027, at the JW Marriott Los Angeles L.A. Live in Los Angeles, California.
- What research themes are expected?
- Based on the 2026 program and 2027 theme, anticipated areas include cancer vaccines, engineered T cells for solid tumors and combinations with checkpoint inhibitors or other immune modulators.
- Do conference findings establish approved treatment benefits?
- No. Many approaches remain investigational, and early-phase conference results are hypothesis-generating signals rather than confirmed clinical benefits or regulatory approval.
Sources
- AACR Immuno-Oncology Conference (AACR IO 2027) official meeting page, American Association for Cancer Research, 2026, https://www.aacr.org/meeting/aacr-io-2027/
- AACR IO 2027 Abstracts and Deadlines page, American Association for Cancer Research, 2026, https://www.aacr.org/meeting/aacr-io-2027/abstracts/
- AACR IO 2027 Prospectus (PDF), American Association for Cancer Research, 2026, https://www.aacr.org/wp-content/uploads/2026/10/AACR-IO-2027_-Prospectus.pdf
- AACR IO 2026 Keynote Highlights: Cancer Vaccines Are Here, and Upgrading T Cells To Thrive in the Tumor Microenvironment, AACR Blog, 2026, https://www.aacr.org/blog/2026/02/20/aacr-io-2026-keynote-highlights-cancer-vaccines-are-here-and-upgrading-t-cells-to-thrive-in-the-tumor-microenvironment/
- Highlights From AACR IO 2026: Breaching the Tumor Microenvironment Fortress With New CAR T and Chimeras, AACR Blog, 2026, https://www.aacr.org/blog/2026/03/06/highlights-from-aacr-io-2026-breaching-the-tumor-microenvironment-fortress-with-new-car-t-and-chimeras/
Related Articles
- Research & Industry
ASCO Annual Meeting 2027: What to Expect From Oncology's Biggest Stage
The world's largest clinical oncology meeting returns to Chicago in June 2027, with cell therapy, immunotherapy, and antibody-drug conjugate research expected to headline the scientific program once again.
- Research & Industry
CAR-T Therapy for Autoimmune Disease in France: What's Actually Happening
France hosts investigational CAR-T trials for severe lupus, but September 2026 safety pauses underscore serious risks and the absence of an approved autoimmune therapy.
- Research & Industry
2027 ASCO Genitourinary Cancers Symposium: What's Coming to San Francisco
A preview of ASCO GU 2027 in San Francisco: dates, sponsors, immunotherapy research trends and why conference findings aren't treatment approvals.